Skip to main content

Cabaletta Bio’s and Gracell’s stock falls sharply as FDA investigates risks of CAR-T therapy

Shares of small biotech companies involved in CAR-T therapies plunged Tuesday as the FDA said it was investigating potential cancer risks.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.